ARE ANTIOSTEOPOROTIC DRUGS EFFECTIVE IN THE MANAGEMENT OF OSTEOARTHRITIS?

ARE ANTIOSTEOPOROTIC DRUGS EFFECTIVE IN THE MANAGEMENT OF OSTEOARTHRITIS?

Detalhes bibliográficos
Autor principal:	Cooper, C
Formato:	Conference item
Publicado em:	2013

Registos relacionados

The antiosteoporotic effect of oxymatrine compared to testosterone in orchiectomized rats
Por: Anwaar M. Shaban, et al.
Publicado em: (2025-01-01)

The study of antiosteoporotic action of nanoparticulated resveratrol and losartan
Por: N. U. Koklina, et al.
Publicado em: (2014-12-01)

Calcium Phosphate/Hyaluronic Acid Composite Hydrogels for Local Antiosteoporotic Drug Delivery
Por: Alise Svarca, et al.
Publicado em: (2022-07-01)

Repurposing the Strontium Ranelate Antiosteoporotic Drug as a New Outstanding Biocompatible Blue Dye
Por: Luca M. Sihn, et al.
Publicado em: (2023-09-01)

Isolation of antiosteoporotic compounds from seeds of Sophora japonica.
Por: Hossam M Abdallah, et al.
Publicado em: (2014-01-01)

Antiosteoporotic Activity of Anthraquinones from Morinda officinalis on Osteoblasts and Osteoclasts
Por: Cheng-Jian Zheng, et al.
Publicado em: (2009-01-01)

Atherosclerosis and Osteoporosis. Common Targets for the Effects of Cardiovascular and Anti-Osteoporotic Drugs (Part II). The Effect of Antiosteoporotic Drugs on the Vascular Wall State
Por: I. A. Skripnikova, et al.
Publicado em: (2019-07-01)

Antiosteoporotic effects of Alpinia officinarum Hance through stimulation of osteoblasts associated with antioxidant effects
Por: Yanjie Su, et al.
Publicado em: (2016-01-01)

Variation in Antiosteoporotic Drug Prescribing and Spending Across Spain. A Population-Based Ecological Cross-Sectional Study
Por: Gabriel Sanfélix-Gimeno, et al.
Publicado em: (2018-04-01)

Discovery of a Potent Antiosteoporotic Drug Molecular Scaffold Derived from Angelica sinensis and Its Bioinspired Total Synthesis
Por: Jian Zou, et al.
Publicado em: (2024-02-01)

Study on the antioxidant and antiosteoporotic activities of the oyster peptides prepared by ultrasound-assisted enzymatic hydrolysis
Por: Zhengze Quan, et al.
Publicado em: (2025-01-01)

Treatment thresholds and minimal clinically important effect sizes of antiosteoporotic medication-Survey among physicians and lay persons in Germany.
Por: Piet van der Keylen, et al.
Publicado em: (2022-01-01)

Potential antiosteoporotic effect of ginkgo biloba extract via regulation of SIRT1-NF-kB signaling pathway
Por: Zhuoze Li, et al.
Publicado em: (2020-06-01)

Antiosteoporotic activity of lupeol on postmenopausal symptoms through promoting estrogenic activity and bone markers in ovariectomized rats
Por: Tanmayee Bhalerao, et al.
Publicado em: (2024-11-01)

Association of Antiosteoporotic Medication Bisphosphonates and Denosumab with Primary Breast Cancer: An Electronic Health Record Cohort Study
Por: Alexander Stanoyevitch, et al.
Publicado em: (2021-08-01)

Comparing the Efficacy of Antiosteoporotic Drugs in Preventing Periprosthetic Bone Loss Following Total Hip Arthroplasty: A Systematic Review and Bayesian Network Meta‐Analysis
Por: Yi Tang, et al.
Publicado em: (2024-10-01)

PARAMETERS OF BONE METABOLISM IN PRE-AND POSTMENOPAUSAL WOMEN WITH TYPE 2 DIABETES MELLITUS IN THE RATIONALE FOR THE CHOICE OF ANTIOSTEOPOROTIC THERAPY
Por: L A Ruyatkina, et al.
Publicado em: (2013-12-01)

Antiosteoporotic Effects and Proteomic Characterization of the Target and Mechanism of an Er-Xian Decoction on Osteoblastic UMR-106 and Osteoclasts Induced From RAW264.7
Por: Yu-Shan Li, et al.
Publicado em: (2010-07-01)

Antidiabetic and antiosteoporotic pharmacotherapies for prevention and treatment of type 2 diabetes-induced bone disease: protocol for two network meta-analyses
Por: Stephanie Sanger, et al.
Publicado em: (2020-01-01)

Overuse and Underuse of Antiosteoporotic Treatments According to Highly Influential Osteoporosis Guidelines: A Population-Based Cross-Sectional Study in Spain.
Por: Gabriel Sanfélix-Gimeno, et al.
Publicado em: (2015-01-01)

Evaluation of bone tissue remodeling and mineral metabolism in elderly patients who have not been previously examined and have received no antiosteoporotic therapy
Por: S B Malichenko, et al.
Publicado em: (2012-03-01)

Evaluation of bone tissue remodeling and mineral metabolism in elderly patients who have not been previously examined and have received no antiosteoporotic therapy
Por: S B Malichenko, et al.
Publicado em: (2012-03-01)

Reaction of 3-Amino-1,2,4-Triazole with Diethyl Phosphite and Triethyl Orthoformate: Acid-Base Properties and Antiosteoporotic Activities of the Products
Por: Patrycja Miszczyk, et al.
Publicado em: (2017-02-01)

Bioregulatory drugs in osteoarthritis management
Por: O. A. Shavlovskaya
Publicado em: (2019-03-01)

Ligustrum japonicum Thunb. Fruits Exert Antiosteoporotic Properties in Bone Marrow-Derived Mesenchymal Stromal Cells via Regulation of Adipocyte and Osteoblast Differentiation
Por: Jung Hwan Oh, et al.
Publicado em: (2021-01-01)

Medical management of osteoarthritis
Por: Walker-Bone, K, et al.
Publicado em: (2000)

AN IN VITRO ANTIOSTEOPOROTIC ACTIVITY OF 96% ETHANOL EXTRACT OF Abelmoschus manihot L. MEDIK LEAVES USING MC3T3-E1 PREOSTEOBLAST CELLS
Por: Agnis Pondinekaria Aditama, et al.
Publicado em: (2016-12-01)

ANTI-INFLAMMATORY DRUGS IN MANAGEMENT OF KNEE OSTEOARTHRITIS
Por: Usman Aziz, et al.
Publicado em: (2019-04-01)

Regular review: medical management of osteoarthritis.
Por: Walker-Bone, K, et al.
Publicado em: (2000)

Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system
Por: Bruyère, O, et al.
Publicado em: (2008)

NEW PERSPECTIVES IN THE TREATMENT OF OSTEOARTHRITIS
Por: Cooper, C
Publicado em: (2012)

NEW PERSPECTIVES IN THE TREATMENT OF OSTEOARTHRITIS
Por: Cooper, C
Publicado em: (2012)

Excess mortality in osteoarthritis.
Por: Cooper, C, et al.
Publicado em: (2011)

Excess mortality in osteoarthritis.
Por: Cooper, C, et al.
Publicado em: (2011)

Topical NSAIDs in osteoarthritis.
Por: Cooper, C, et al.
Publicado em: (2004)

Cardiovascular Drugs and Osteoarthritis: Effects of Targeting Ion Channels
Por: Raminta Vaiciuleviciute, et al.
Publicado em: (2021-09-01)

Controversy About Management of Osteoarthritis with Disease-modifying Anti-rheumatic Drugs
Por: CUI Hanshu, et al.
Publicado em: (2025-01-01)

Strategy for the management of osteoarthritis in multimorbid patients: the balance of effectiveness and safety while choosing drug therapy
Por: K. Yu. Belova, et al.
Publicado em: (2020-08-01)

Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system
Por: Rizzoli René, et al.
Publicado em: (2008-12-01)

Disease-modifying osteoarthritis drugs (DMOADs): new trends in osteoarthritis therapy
Por: O. A. Shavlovskaya, et al.
Publicado em: (2023-11-01)